



# Session Summary

Day 2 : Wed 3rd Sept'14  
Room : Charter 1  
09:10 - 17:00

## Target Validation Approaches in Drug Discovery

For the pharmaceutical industry successful clinical trials are the ultimate yardstick for assessing the value of their efforts in target validation. The continued high rate of compounds failing in clinic trials due to lack of efficacy has triggered serious efforts in many companies to develop a more advanced set of tools and processes for target validation before transferring novel target ideas into lead discovery efforts.

Speakers in this session will outline their approaches for building a compelling case in target validation, i.e. linking modulation of a target in a preclinical setting with the expected outcome of target validation in a clinical setting. The session will cover a range of experimental activities from *in-vitro* biochemical, cellular and biophysical studies towards *in-vivo* studies in disease models all the way towards human genetics and other approaches.

Since target validation can be done both in industry and academia, this area is ideal for public-private partnerships and for pre-competitive collaborations between industry and academia.

**CHAIRS : Lorenz Mayr, AstraZeneca, Andreas Sailer, Novartis**

TIME	SPEAKER	TITLE	
9:10	Session Chairs	Introduction and Welcome	
9:15	Stefan Offermanns, Max Planck Institute	Regulation of metabolism and immune functions through metabolite GPCRs	Session Keynote
10:00	Ulrich Elling, IMBA Institute for Molecular Biotechnology	Genome-wide Functional Genetics in Haploid ES Cells	
10:30	COFFEE BREAK		
11:00	Neil Carragher, University of Edinburgh	Advancing target validation and phenotypic drug discovery strategies through combined high content analysis, intravital imaging and reverse phase protein array technology	
11:30	Poster Taster Session		
12:00	Snapshots		
12:30	LUNCH, Exhibition, Posters, Lunchtime Workshops		
2:00	Sannah Zoffmann, F. Hoffmann-La Roche AG	High-content assays applied to analysis of complex neuronal phenotypes	
2:30	Mark Gemkow, Evotec AG	A High Content Imaging Platform to advance target validation for neurological disorders	
3:00	Rudi Balling, (LCSB) Luxembourg Centre for Systems Biomedicine	Parkinson's Disease – Can systems biology help us out ?	
3:30	COFFEE BREAK		
4:00	Panel Discussion		In Charter 1 ( here )
5:00	Close of Conference / Prizes		
5:15	CLOSE		

Publication date 09/06/14. More detail, abstracts, speaker biogs, etc, are available on our website : [www.elrig.org](http://www.elrig.org)



Get the FREE mobile app [myEventflo](#) for iOS or Android

It's FREE to attend Drug Discovery '14 as a delegate.  
[Register here](#) or go to [www.elrig.org](http://www.elrig.org)